Physician profile
Frank E Mayer
NPI 1598760589
$530.79
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $404 · 2020: $22.87 · 2021: $46.92 · 2022: $56.54.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $170.90 | 2019-2022 | |
| Pfizer INC. | $129.79 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $94.24 | 2019 | |
| Concordia Pharmaceuticals INC. | $53.02 | 2019 | |
| Redhill Biopharma INC. | $22.87 | 2020 | |
| Braintree Laboratories, INC. | $19.17 | 2019 | |
| Romark Laboratories, Lc | $13.71 | 2019 | |
| Array Biopharma INC | $13.63 | 2019 | |
| Janssen Biotech, INC. | $13.46 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Mayer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.